NEW YORK, May 30 - Sangamo Biosciences said Wednesday it has obtained the option to acquire privately-held Gendaq in a stock-for-stock deal worth $39.7 million.

Sangamo, which is currently completing due diligence, has until July 14 to exercise its option to acquire Gendaq, a London-based developer of zinc finger DNA binding proteins for gene regulating gene expression. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

In Science this week: environmental DNA can help in studies of marine animals, and more.